Open AccessRole of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells
Author(s) -
Cathy X. Wang,
Bruce E. Torbett
Publication year - 2015
Publication title -
current opinion in hematology/current opinion in hematology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 97
eISSN - 1080-8213
pISSN - 1065-6251
DOI - 10.1097/moh.0000000000000150
Subject(s) - transduction (biophysics) , biology , microbiology and biotechnology , stem cell , haematopoiesis , endocytic cycle , pi3k/akt/mtor pathway , signal transduction , hematopoietic stem cell , viral vector , gene delivery , genetic enhancement , endocytosis , cell , gene , genetics , recombinant dna , biochemistry
A major goal in repopulating hematopoietic stem cell (HSC) gene therapies is achieving high-efficacy gene transfer, while maintaining robust HSC engraftment and differentiation in vivo. Recent studies have documented that rapamycin treatment of HSC during lentiviral vector transduction enhances gene transfer to human and mouse HSCs and maintains engraftment capacity. In this review, we place into context the role of mammalian target of rapamycin (mTOR) pathways in HSC quiescence and function, endocytic regulation, and lentiviral gene delivery.